Researchers who want to study medical marijuana as a treatment for PTSD say the U.S. government is making it very hard to do so.
The non-profit Multidisciplinary Association For Psychedelic Studies (MAPS) is trying to obtain a supply of cannabis for the first FDA-approved clinical trial of medical marijuana for post-traumatic stress disorder.
Unfortunately, despite the availability of medical marijuana in certain states, the National Institute on Drug Abuse (NIDA) is the only legal source of cannabis for researchers. And compared to the FDA, getting NIDA’s approval for a clinical trial has proven a lot harder.
The team at MAPS, led by Dr. Sue Sisley of the University of Arizona College of Medicine, first approached NIDA to purchase cannabis in 2011, after getting the go-ahead from the FDA. NIDA unanimously rejected the proposal, supposedly due to flaws in the study’s design.